You are here
Approvable Letter Issued for Conivaptan Hydrochloride Injection, Potential Treatment for Hyponatremia
Akihiko Matsubara, President and Chief Operating Officer of Yamanouchi Pharma America, Inc., said, "We are pleased with the approvable designation, and we will work closely with the FDA to bring conivaptan to market as quickly as possible. If approved, we believe that conivaptan will provide another alternative in the management of hyponatremia, a potentially serious condition for which there is currently no approved treatment."
Conivaptan is the second drug Yamanouchi hopes to introduce to the market in the United States.
Developed by Yamanouchi, conivaptan is a novel drug that demonstrated in clinical trials the ability to restore normal sodium levels in patients with hyponatremia. Although there are no drug therapies approved for hyponatremia, current treatments include fluid restriction, diuretics and hypertonic saline solution.
Hyponatremia is estimated to affect 1 percent to 4 percent of hospitalized patients in the United States each year.(1)(2) Congestive heart failure, advanced renal failure, hypothyroidism, chronic hypertension and syndrome of inappropriate antidiuretic hormone (SIADH) are frequently causes of hyponatremia. Dilutional hyponatremia, the most common form of the condition, occurs when retained water dilutes serum sodium content. While many patients with hyponatremia have no symptoms, severe cases are medical emergencies that can result in swelling of the brain, respiratory arrest and death.
References: 1. Tierney WM, Martin DK, Greenlee MC, Zerbe RL, McDonald CJ. The prognosis of hyponatremia at hospital admission. J Gen Intern Med 1986; 1:380-385. 2. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenic role of Vasopressin. Ann Int Med 1985; 102:164-168.
Source: Yamanouchi Pharma America, Inc.